By Brian Jurczyk, President and Chief Executive Officer of Starfire Industries and Chairman of the CEO Roundtable
Many Illinois emerging small businesses benefit from the Small Business Innovation Research and Technology Transfer (SBIR/STTR) federal programs. In 2012, Illinois small businesses received 122 awards amounting to $41 million [see info graphic below]. Through an intensely competitive process, about $2.5 billion per year in early-stage technology funding is funneled into business creation across the United States—generating nearly $18 billion in economic activity, a 7×ROI on tax dollars. This successful federal program is emulated worldwide due to its track record encouraging technology entrepreneurship, value creation and high-paying jobs.
As a result, there is intense competition at the state level to incentivize and attract federal SBIR/STTR dollars into regional economies. In 2012, Illinois small businesses received only 1.4% of the nationwide total despite having 4.2% the U.S. population, the 4th largest concentration of Fortune 500 companies, flagship research universities and national laboratories and superior infrastructure.
As the SBIR/STTR program has evolved through congressional reauthorization, greater emphasis on commercial success probability and risk management have become critical to determining the likelihood of award. Today, awarded firms typically have a minimum of three letters of support including a “matching investment” contribution from a regional fund, State program or industrial partner—in addition to a compelling tech solution. Teaming with companies and universities lowers technical risk, industrial partnership and customer “buy-in” lower market risk and in-kind or cash matching investments lower financial risk. In my own experience, our company which recently expanded beyond its incubation at the University of Illinois Urbana Champaign’s Research Park, leveraged a $100k State matching grant into a $750k Fortune 500 partnership bringing in over $3.5 million in federal dollars from two agencies.
Through discussions at our regional CEO Roundtable Forum, which brings together executives of technology businesses in Champaign-Urbana to address business operations and best practices, there is a consistent theme focusing on leverage and validation. An SBIR/STTR technology has three key validating attributes: (1) it has been vetted by a team of technical experts and judged to have merit, (2) it fulfills an unmet market need with a potential sales channel and (3) there is a federal agency willing to provide R&D funds for proof-of-concept. As a result, an SBIR/STTR technology is already a lower risk investment for industrial partners and early adopter customers. The key is cultivating a corporate champion, arming them with transparent means to leverage internal support for the SBIR/STTR firm and using external resource leverage to capture the investment—all within a short timeframe typically less than 2 months.
It is critical that strategies directed towards aiding Illinois high-tech small businesses recognize these factors. Given Illinois’ diverse industrial base and world-class universities, there is immense potential to use the SBIR/STTR program to make Illinois’ small and already-established businesses more competitive through locally-grown technology. In the process we will create sustainable economic growth through the creation of new products, processes and quality high-paying jobs.
Did You Know?
The SBIR program is aimed at small high-tech businesses exploring promising new technologies independently or in collaboration with other private sector partners. STTR awards focus on small business collaborations with universities or nonprofit research organizations for purposes of technology commercialization. In 2012, Illinois’ high-tech small businesses won 121 SBIR/STTR awards and brought in over $41 million dollars in early stage federal funding for feasibility (Phase I) and prototyping (Phase II) projects. SBIR Phase I awards of up to $150,000 make up the majority of awards whereas SBIR Phase II awards, which can be as high as a million dollars, account for over half of the total value of all awards. Increasing the numbers of SBIR I and STTR I awards is critical since these awards are prerequisites for the larger Phase II. In 2011, legislation was passed to gradually increase the size of all awards, with SBIR Phase II awards reaching $1.5 million by 2017.
Watch and Listen:
University of Illinois faculty and innovators explain the role of SBIR/STTR in technology commercialization
Chicago-based company Sciaky Inc. discusses its SBIR-funded technology that could disrupt the manufacturing of high-value parts
- University of Illinois Research Park lectures on SBIR/STTR Funding
- iBIO PROPEL Grant Writing Workshops for SBIR/STTR, Sept 16th -17th
- DCEO and Bradley University’s Turner Center for Entrepreneurship team up to offer SBIR-STTR Grant Writing Assistance Awards
- NASA’s impact in Illinois through SBIR and STTR: a tech transfer perspective
- Chicago data storage company, CleverSafe, get $55 million in growth stage venture capital
- University of Chicago Proof-of-Concept innovation fund announces six winners
- Illinois-based Motorola Mobility takes on the mobile-device market
- Chicago’s trading companies and their software innovation are a magnet for top programming talent
Illinois Innovation Network Featured Resource:
Each month, the Illinois Science and Technology Coalition features a service or resource available to innovators and entrepreneurs in the state of Illinois on the Illinois Innovation Network. To learn more and add your resource to the Network, click here.
Advanced Photon Source at Argonne National Laboratory
The Advanced Photon Source (APS) at Argonne National Laboratory is one of the most technologically complex machines in the world. This premier national research facility provides the brightest x-ray beams in the Western Hemisphere to more than 5,000 (and growing) scientists from around the United States and the world. These scientists come to the APS from universities, industry, medical schools, and other research institutions.